Dr. Chan Tim Wai - Clinical Oncology
Specialist in Clinical Oncology
Highlights
- MCHK RegisteredVerified
- Specialist in Clinical OncologyBachelor of Medicine and Bachelor of Surgery (MBBS) · Hong Kong College of Radiologists · Medical degree 2007
- InsuranceBeing compiled｜See details
About
Dr. Chan Tim Wai is a registered Clinical Oncology specialist in Hong Kong.
Education
Specialist in Clinical Oncology
- Bachelor of Medicine and Bachelor of Surgery (MBBS)Bachelor of Medicine and Bachelor of Surgery (MBBS)2007
Hong Kong Academy of Medicine fellowships
- FHKCRFellow, Hong Kong College of Radiologists
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Chan Tim Wai? Claim page and update insurance →
FAQ
Is Dr. Chan Tim Wai any good?
Dr. Chan Tim Wai is a registered Clinical Oncology specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Chan Tim Wai do?
Dr. Chan Tim Wai practises in Clinical Oncology.
Are you Dr. Chan Tim Wai? Claim this page to update and manage.
ClaimResearch and publications
8 papers
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer.Clinical genitourinary cancer · 2024
- Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.Frontiers in oncology · 2024
- Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients.Asia-Pacific journal of clinical oncology · 2021
- Prostate cancer management in the era of COVID-19: Recommendations from the Hong Kong Urological Association and Hong Kong Society of Uro-oncology.Asia-Pacific journal of clinical oncology · 2021
- Hong Kong Urological Association-Hong Kong Society of Uro-Oncology consensus statements on the management of advanced prostate cancer-2019 Updates.Asia-Pacific journal of clinical oncology · 2021
- Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.BJU international · 2019
- Management of advanced prostate cancer in Hong Kong: Insights from an APCCC-Derived survey.Asia-Pacific journal of clinical oncology · 2019
- Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.BJU international · 2018
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer